#HVO hVIVO Plc – £6.3M HRV CONTRACT SIGNED WITH BIOTECH CLIENT January 2, 2024 – Posted in: hVIVO (HVO)

Highlights ·    Study to enter hVIVO’s state-of-the-art Canary Wharf quarantine facilities in H2 2024 ·    Potential to enhance value of the client’s antiviral by generating efficacy data in HRV   hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it has signed a £6.3m contract with a biotechnology client to test its antiviral candidate using the hVIVO Human Rhinovirus (HRV –…

Continue reading